title: Antidepressant activity: contribution of brain microdialysis in knock-out mice to the understanding of BDNF/5-HT transporter/5-HT autoreceptor interactions.
abstract: Why antidepressants vary in terms of efficacy is currently unclear. Despite the leadership of selective serotonin reuptake inhibitors (SSRIs) in the treatment of depression, the precise neurobiological mechanisms involved in their therapeutic action are poorly understood. A better knowledge of molecular interactions between monoaminergic system, pre- and post-synaptic partners, brain neuronal circuits and regions involved may help to overcome limitations of current treatments and identify new therapeutic targets. Intracerebral in vivo microdialysis (ICM) already provided important information about the brain mechanism of action of antidepressants first in anesthetized rats in the early 1990s, and since then in conscious wild-type or knock-out mice. The principle of ICM is based on the balance between release of neurotransmitters (e.g., monoamines) and reuptake by selective transporters [e.g., serotonin transporter for serotonin 5-hydroxytryptamine (5-HT)]. Complementary to electrophysiology, this technique reflects pre-synaptic monoamines release and intrasynaptic events corresponding to ≈80% of whole brain tissue content. The inhibitory role of serotonergic autoreceptors infers that they limit somatodendritic and nerve terminal 5-HT release. It has been proposed that activation of 5-HT1A and 5-HT1B receptor sub-types limits the antidepressant-like activity of SSRIs. This hypothesis is based partially on results obtained in ICM experiments performed in naïve, non-stressed rodents. The present review will first remind the principle and methodology of ICM performed in mice. The crucial need of developing animal models that display anxiety and depression-like behaviors, neurochemical and brain morphological phenotypes reminiscent of these mood disorders in humans, will be underlined. Recently developed genetic mouse models have been generated to independently manipulate 5-HT1A auto and heteroreceptors and ICM helped to clarify the role of the pre-synaptic component, i.e., by measuring extracellular levels of neurotransmitters in serotonergic nerve terminal regions and raphe nuclei. Finally, we will summarize main advantages of using ICM in mice through recent examples obtained in knock-outs (drug infusion through the ICM probe allows the search of a correlation between changes in extracellular neurotransmitter levels and antidepressant-like activity) or alternatives (infusion of a small-interfering RNA suppressing receptor functions in the mouse brain). We will also focus this review on post-synaptic components such as brain-derived neurotrophic factor in adult hippocampus that plays a crucial role in the neurogenic and anxiolytic/antidepressant-like activity of chronic SSRI treatment. Limitations of ICM will also be considered.
authors: EA 3544 "Pharmacologie des troubles anxio-dépressifs et Neurogenèse", Faculté de Pharmacie, Université Paris-Sud Chatenay-Malabry, France.
authors: Alain M
authors: AM
authors: Gardier
keywords: BDNF; antidepressants; autoreceptors; knock-out mice; microdialysis; serotonin
references: J Neurosci. 1986 Oct;6(10):2796-801
references: 3020184
references: Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14476-81
references: 9826725
references: J Neurochem. 1997 Sep;69(3):1322-5
references: 9282960
references: Science. 2006 Jul 28;313(5786):536-40
references: 16873667
references: Neuropharmacology. 2008 Nov;55(6):1006-14
references: 18761360
references: Neuroreport. 1995 Dec 29;7(1):353-9
references: 8742487
references: J Clin Psychopharmacol. 1987 Dec;7(6 Suppl):24S-35S
references: 3323264
references: J Neurosci. 1994 May;14(5 Pt 2):3036-47
references: 8182457
references: Neuroscientist. 2010 Oct;16(5):578-91
references: 20889967
references: J Neurosci. 2003 Sep 24;23(25):8788-99
references: 14507979
references: Neuron. 2009 May 28;62(4):479-93
references: 19477151
references: J Neurosci. 2000 Dec 15;20(24):9104-10
references: 11124987
references: Neuropharmacology. 2011 Sep;61(3):478-88
references: 21333660
references: Eur J Pharmacol. 2010 Feb 25;628(1-3):83-90
references: 19944680
references: Arch Int Pharmacodyn Ther. 1972;198(1):9-21
references: 4626478
references: Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):15049-54
references: 9844013
references: Behav Pharmacol. 2009 Feb;20(1):18-32
references: 19179848
references: Eur J Pharmacol. 2008 Jun 10;587(1-3):90-8
references: 18474368
references: J Chromatogr A. 2008 Sep 26;1205(1-2):144-9
references: 18752800
references: J Clin Psychiatry. 2011 Jul;72(7):962-9
references: 21034693
references: Synapse. 1991 Sep;9(1):60-5
references: 1796352
references: Neuropharmacology. 2010 Feb;58(2):346-50
references: 19887076
references: J Neurosci Methods. 2004 Dec 30;140(1-2):81-92
references: 15589338
references: Naunyn Schmiedebergs Arch Pharmacol. 1996 Dec;354(6):785-90
references: 8971740
references: Synapse. 1995 Jul;20(3):225-33
references: 7570354
references: Neurosci Lett. 1996 Nov 22;219(2):123-6
references: 8971795
references: Eur J Pharmacol. 2004 May 10;492(1):41-8
references: 15145704
references: Annu Rev Psychol. 2006;57:117-37
references: 16318591
references: Curr Drug Targets. 2006 Feb;7(2):139-47
references: 16475955
references: J Neurochem. 2003 Jul;86(1):13-24
references: 12807420
references: Neurochem Int. 2011 Aug;59(2):185-91
references: 21693154
references: J Neurosci Methods. 2004 Dec 30;140(1-2):53-7
references: 15589334
references: Brain Res. 2002 Jun 28;942(1-2):109-19
references: 12031859
references: J Neurosci. 2002 Aug 1;22(15):6766-72
references: 12151556
references: Brain Res Bull. 2002 Jan 1;57(1):93-102
references: 11827741
references: Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10734-9
references: 9724773
references: Int J Neuropsychopharmacol. 2009 Aug;12(7):905-15
references: 19236729
references: Neuron. 2010 Jan 14;65(1):1-2
references: 20152106
references: Nature. 2005 Jul 7;436(7047):103-7
references: 16001069
references: Mol Pharmacol. 2007 Dec;72(6):1411-8
references: 17890358
references: C R Acad Sci III. 2001 May;324(5):433-41
references: 11417564
references: J Neurosci. 2001 Oct 15;21(20):8188-97
references: 11588191
references: Br J Pharmacol. 2013 Jan;168(1):103-16
references: 22233336
references: Nature. 1977 Apr 21;266(5604):730-2
references: 559941
references: Mol Psychiatry. 2012 Jun;17(6):567
references: 22617870
references: J Neurochem. 1983 Dec;41(6):1769-73
references: 6196446
references: J Neurosci. 2011 Apr 20;31(16):6008-18
references: 21508226
references: J Clin Psychiatry. 1996;57 Suppl 10:34-41; discussion 42-3
references: 8917130
references: Science. 1994 Sep 23;265(5180):1875-8
references: 8091214
references: J Pharmacol Exp Ther. 1990 Jan;252(1):410-8
references: 2137177
references: J Neurochem. 2004 Apr;89(1):54-63
references: 15030389
references: J Clin Psychiatry. 2001;62 Suppl 15:12-7
references: 11444761
references: Psychopharmacology (Berl). 1985;85(3):367-70
references: 3923523
references: J Neurochem. 2004 Mar;88(6):1373-9
references: 15009637
references: Neuropsychopharmacology. 2005 Jul;30(7):1269-77
references: 15702136
references: Science. 2006 Oct 6;314(5796):140-3
references: 17023662
references: Eur J Pharmacol. 1985 Mar 12;109(3):381-7
references: 2580723
references: Neuropsychopharmacology. 2006 Oct;31(10):2162-72
references: 16452992
references: J Chromatogr B Analyt Technol Biomed Life Sci. 2007 May 1;850(1-2):303-9
references: 17166782
references: Neurosci Lett. 1993 Aug 6;158(1):44-6
references: 7901816
references: J Neurochem. 2001 Feb;76(3):865-71
references: 11158258
references: Science. 1992 Jul 10;257(5067):206-11
references: 1321493
references: Int J Neuropsychopharmacol. 2008 Feb;11(1):79-92
references: 17559709
references: J Neurosci Res. 2007 Nov 1;85(14):3030-5
references: 17492791
references: Mol Pharmacol. 1998 Apr;53(4):649-55
references: 9547354
references: Nature. 2002 Mar 28;416(6879):396-400
references: 11919622
references: Brain Res. 1996 Oct 21;737(1-2):221-30
references: 8930369
references: J Neurochem. 1997 Nov;69(5):2019-25
references: 9349547
references: Br J Pharmacol. 2003 Nov;140(6):1128-36
references: 14530210
references: Cell. 2008 Jan 11;132(1):125-36
references: 18191226
references: Eur J Pharmacol. 1995 Nov 14;286(2):213-7
references: 8605960
references: J Neurochem. 1996 Aug;67(2):669-76
references: 8764594
references: Science. 2003 Aug 8;301(5634):805-9
references: 12907793
references: J Pharmacol Exp Ther. 1986 Jun;237(3):987-94
references: 2423685
references: Neuron. 2010 Jan 14;65(1):40-52
references: 20152112
references: Eur J Pharmacol. 2003 Feb 28;463(1-3):185-97
references: 12600710
references: Neuro Endocrinol Lett. 2010;31(1):4-10
references: 20150867
references: Fundam Clin Pharmacol. 1996;10(1):16-27
references: 8900496